A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a)...
A Phase III, randomised, double-blind, placebo-controlled, parallel-group study to assess the effect of AZD0780 on low-density lipoprotein cholesterol (LDL-C) in patients with elevated LDL- C and...
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic...
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients...
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on the Risk of...
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR,...
Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial
Randomized, Multi-Center, Event-Driven Trial of TAVI versus SAVR in Patients with Symptomatic Severe Aortic Valve Stenosis and Intermediate Risk of Mortality, as assessed by STS-Score
Titel der Studie: Eine randomisierte, doppelblinde Phase-III-Studie zur Beurteilung der Wirksamkeit und Sicherheit von einmal täglich 10 mg Empagliflozin im Vergleich zu Placebo bei Patienten mit...
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction...
EDOXABAN VERSUS STANDARD OF CARE AND THEIR EFFECTS ON CLINICAL OUTCOMES IN PATIENTS HAVING UNDERGONE TRANSCATHETER AORTIC VALVE IMPLANTATION – IN ATRIAL FIBRILLATION
First prospective randomized trial to examine a differential therapeutic response in symptomatic patients with non-obstructive coronary artery disease after coronary physiological testing
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease on Stable Lipid Lowering Therapy Requiring...
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease, or at High Risk for Cardiovascular Disease,...
Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at...
Randomized, Open label, Phase 3 Study to Evaluate the Efficacy and Safety of Lerodalcibep (LIB003) compared to Inclisiran in Patients With Cardiovascular Disease, or at High Risk for Cardiovascular...
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With...
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) Who...
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection...
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced...
OCEAN(a) Outcomes Studie zur Senkung von Lipoprotein (a) mit OLPASIRAN (si RNA)
Laufzeit:
15.06.2023 - 16.12.2026
|
:
|
:
Herz
A Double-blind, Randomized, Placebo-controlled, Multicenter study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease...
PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO COMPARE THE EFFECT OF DIFFERENT DOSES OF ALN-PCSSC GIVEN AS SINGLE OR MULTIPLE SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK...
A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO EVALUATE THE EFFECT OF 300 MG OF INCLISIRAN SODIUM GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE...
An open label, active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and...
A long-term extension trial of the phase III lipid-lowering trials to assess the effect of long-term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and...
Effect of antifibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI) in aortic stenosis patients with high fibrotic burden
Implantable cardiac monitorS in high-risk post-infarction patients with cardiac autonoMic dysfunction And modeRaTely reduced left ventricular ejection fraction
A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of...
Protokolltitel: Doppelblinde, randomisierte, Placebo-kontrollierte, multizentrische Studie zur Beurteilung der Auswirkungen von Evolocumab auf größere kardiovaskuläre Ereignisse bei Patienten mit hohem...
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection...